IOL Chemicals & Pharmaceuticals submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the National Stock Exchange of India Limited and BSE Limited on August 7, 2026. The filing, mandated under Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, details the company’s environmental, social, and governance performance. For FY26, the company reported a turnover of ₹2319.06 crore and a net worth of ₹1798.38 crore. The report highlights significant sustainability achievements, including 100% water neutrality and an 8.8% reduction in Scope 1 and Scope 2 greenhouse gas emission intensity compared to FY25, despite a 43% increase in API production volumes.

The BRSR forms part of the company’s Integrated Annual Report for FY26 and was assured by Intertek India Private Limited, which provided reasonable assurance on the disclosures. Abhay Raj Singh, Senior Vice President and Company Secretary, signed the submission. The report covers standalone operations, with the company maintaining one plant and three offices in India. Key business activities include the manufacturing of Active Pharma Ingredients and Intermediates, contributing 59.66% of turnover, and Specialty Chemicals, contributing 39.43%. Exports accounted for 24% of total turnover, serving markets in 70 countries.

Environmental Performance

IOL Chemicals & Pharmaceuticals reported total energy consumption of 2898 Tera Joules in FY26, comprising 2221.6 Tera Joules from renewable sources and 676.4 Tera Joules from non-renewable sources. Energy intensity per rupee of turnover was recorded at 0.000000125 Tera Joules. The company achieved 100% water neutrality, with total water withdrawal at 355,796 kilolitres and consumption at 355,796 kilolitres. A Zero Liquid Discharge process is implemented to treat, recycle, and reuse water in cooling towers.

Greenhouse gas emissions data reveals Total Scope 1 emissions of 60,731.8 metric tonnes of CO2 equivalent and Total Scope 2 emissions of 16,681.2 metric tonnes of CO2 equivalent. Total Scope 3 emissions were 85,528.6 metric tonnes of CO2 equivalent. The company noted that while absolute emissions rose due to production expansion, emission intensity decreased. Initiatives such as solar panel installation, waste-to-wealth projects, and supplier capacity building under the “Prayas” initiative contributed to these gains.

Social and Governance Highlights

The company employed 3,592 individuals as of the end of FY26, including 3,095 permanent employees. Women constituted 12.5% of the Board of Directors but held no positions in Key Management Personnel. The turnover rate for permanent employees was 16.00%. IOL Chemicals & Pharmaceuticals reported zero fatalities and one lost-time injury among employees during the year. The company maintains ISO 45001:2018 certification for occupational health and safety, covering 100% of its plants and offices.

Governance structures include a Corporate Social Responsibility Committee chaired by Rajender Mohan Malla. The company received two shareholder complaints in FY26, both resolved by year-end. No complaints were filed regarding sexual harassment, discrimination, or child labor. The company adheres to SA 8000:2014 social accountability standards and conducts regular training on human rights and ethical conduct for employees and value chain partners. Related party transactions accounted for 6.83% of purchases and 0.95% of investments, with no related-party sales or loans disclosed.

IOL Chemicals & Pharmaceuticals has received approval from the National Medical Products Administration (NMPA), China, for its Clopidogrel Bisulfate Active Pharmaceutical Ingredient (API). The Centre for Drug Evaluation (CDE) of the NMPA granted this approval on July 14, 2026. This regulatory clearance enables the company to expand its market access in China, adding to its existing valid Certificate of Suitability (CEP) for the same product.

Regulatory Approval Details

The approval from China's NMPA pertains to Clopidogrel Bisulfate, a widely used API in the formulation of antiplatelet medications. The following table summarizes the key details of this development:

Significance of the Approval

Securing NMPA approval is a rigorous process that requires compliance with China's stringent pharmaceutical manufacturing and quality standards. This clearance allows IOL Chemicals & Pharmaceuticals to market and supply Clopidogrel Bisulfate API to pharmaceutical manufacturers operating within China. The development highlights the company's capability to meet international regulatory requirements across key global markets.